Flexion Therapeutics (FLXN) Gets a Hold Rating from Needham

In a report released today, Serge Belanger from Needham maintained a Hold rating on Flexion Therapeutics (FLXNResearch Report). The company’s shares closed last Monday at $9.18.

According to TipRanks.com, Belanger is a 3-star analyst with an average return of 4.6% and a 42.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Flexion Therapeutics has an analyst consensus of Hold, with a price target consensus of $10.50.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $13.66 and a one-year low of $4.30. Currently, Flexion Therapeutics has an average volume of 1.81M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.

Read More on FLXN: